{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:12:17Z","timestamp":1790874737437,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"name":"Bath Institute for Rheumatic Diseases"},{"name":"Intramural grant (SGPGIMS) 2018"},{"name":"Arthritis Australia Ken Muirden Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Myositis-specific and associated autoantibodies are important biomarkers in routine clinical use. We assessed local testing performance for myositis autoantibodies by comparing line immunoassay (LIA) to protein radio-immunoprecipitation and identifying clinical characteristics associated with each myositis autoantibody in the MyoCite cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum samples from patients within the MyoCite cohort, a well-characterized retro-prospective dataset of adult and juvenile idiopathic inflammatory myopathy (IIM) patients in Lucknow, India (2017\u20132020), underwent LIA at Sanjay Gandhi Postgraduate Institute of Medical Science (SGPGIMS), Lucknow. Immunoprecipitation of 147 IIM patients\u2019 serum samples (125 adult-onset, 22 juvenile-onset) was conducted at the University of Bath, with researchers blind to LIA results. LIA performance was assessed against immunoprecipitation as the reference standard, measuring sensitivity, specificity and inter-rater agreement. Univariate and multivariate logistic regression determined clinical associations for specific myositis-specific autoantibodies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Immunoprecipitation identified myositis autoantibodies in 56.5% (n\u2009=\u200983) of patient samples, with anti-Jo1 (n\u2009=\u200916; 10.9%) as the most common, followed by anti-MDA5 (n\u2009=\u200914, 9.5%). While LIA showed good agreement for anti-Jo1, anti-PL7 and anti-PL12 (Cohen's \u03ba 0.79, 0.83 and 1, respectively), poor agreement was observed in other subgroups, notably anti-TIF1\u03b3 (Cohen's \u03ba 0.21). Strongly positive samples, especially in myositis-specific autoantibodies, correlated more with immunoprecipitation results. Overall, 59 (40.1%) samples exhibited non-congruence on LIA and immunoprecipitation, and \u03ba values for LIAs for anti-TIF1\u03b3, anti-Ku, anti-PmScl, anti-Mi2 and anti-SAE ranged between 0.21 and 0.60.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>While LIA reliably detected anti-Jo1, anti-PL7, anti-PL12, anti-MDA5 and anti-NXP-2, it also displayed false positives and negatives. Its effectiveness in detecting other autoantibodies, such as anti-TIF1\u03b3, was poor.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae167","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T01:13:11Z","timestamp":1710378791000},"page":"2363-2371","source":"Crossref","is-referenced-by-count":24,"title":["Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-7204","authenticated-orcid":false,"given":"Aravinthan","family":"Loganathan","sequence":"first","affiliation":[{"name":"Royal National Hospital of Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust , Bath, UK"},{"name":"Department of Life Sciences, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-2990","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, SGPGIMS , Lucknow, India"},{"name":"Department of Rheumatology, Royal Wolverhampton Hospital NHS Trust , Wolverhampton, UK"},{"name":"Division of Musculoskeletal and Dermatological Sciences, Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester , Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rudge","sequence":"additional","affiliation":[{"name":"Department of Mathematical Sciences, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Bowler","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"McMorrow","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2014-3925","authenticated-orcid":false,"given":"R","family":"Naveen","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, SGPGIMS , Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika K","family":"Anuja","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, SGPGIMS , Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-027X","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, SGPGIMS , Lucknow, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tansley","sequence":"additional","affiliation":[{"name":"Royal National Hospital of Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust , Bath, UK"},{"name":"Department of Life Sciences, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"2024091608262088300_keae167-B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024091608262088300_keae167-B2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","article-title":"Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry","volume":"41","author":"Mehta","year":"2021","journal-title":"Rheumatol Int"},{"key":"2024091608262088300_keae167-B3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.semarthrit.2019.03.005","article-title":"Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients","volume":"49","author":"Kang","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024091608262088300_keae167-B4","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/rheumatology\/keab108","article-title":"Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study","volume":"60","author":"Yamasaki","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024091608262088300_keae167-B5","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1007\/s10067-022-06291-z","article-title":"Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China","volume":"41","author":"Wen","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2024091608262088300_keae167-B6","doi-asserted-by":"crossref","first-page":"101486","DOI":"10.1016\/j.berh.2020.101486","article-title":"Pitfalls in the diagnosis of myositis","volume":"34","author":"Chinoy","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024091608262088300_keae167-B7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41927-020-00132-9","article-title":"Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results","volume":"4","author":"To","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2024091608262088300_keae167-B8","first-page":"1048","article-title":"Distinct dermatomyositis populations are detected with different autoantibody assay platforms","volume":"37","author":"Fiorentino","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2024091608262088300_keae167-B9","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/1756-185X.14174","article-title":"Performance of myositis-specific antibodies detected on myositis line immunoassay to diagnose and sub-classify patients with suspected idiopathic inflammatory myopathy, a retrospective records-based review","volume":"24","author":"Beaton","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2024091608262088300_keae167-B10","doi-asserted-by":"crossref","first-page":"100013","DOI":"10.1016\/j.jtauto.2019.100013","article-title":"Frequencies and clinical associations of myositis-related antibodies in The Netherlands: a one-year survey of all Dutch patients","volume":"2","author":"Platteel","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"2024091608262088300_keae167-B11","doi-asserted-by":"crossref","first-page":"804037","DOI":"10.3389\/fimmu.2022.804037","article-title":"A commercial anti-TIF1\u03b3 ELISA is superior to line and dot blot and should be considered as part of routine myositis-specific antibody testing","volume":"13","author":"Mulhearn","year":"2022","journal-title":"Front Immunol"},{"key":"2024091608262088300_keae167-B12","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024091608262088300_keae167-B13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","article-title":"Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies","volume":"9","author":"R\u00f6nnelid","year":"2009","journal-title":"Autoimmun Rev"},{"key":"2024091608262088300_keae167-B14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024091608262088300_keae167-B15","doi-asserted-by":"crossref","first-page":"975939","DOI":"10.3389\/fimmu.2022.975939","article-title":"The use of ELISA is comparable to Immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population","volume":"13","author":"Loganathan","year":"2022","journal-title":"Front Immunol"},{"key":"2024091608262088300_keae167-B16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2020.10.014","article-title":"Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis","volume":"51","author":"Gupta","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2024091608262088300_keae167-B17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/injr.injr_95_20","article-title":"Development of the myocite biobank: cost-efficient model of public sector investigator-driven biobank for idiopathic inflammatory myositis","volume":"15","author":"Naveen","year":"2020","journal-title":"Indian J Rheumatol"},{"key":"2024091608262088300_keae167-B18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/injr.injr_40_19","article-title":"Meeting report: myoIN\u2014Pan-India collaborative network for myositis research","volume":"14","author":"Gupta","year":"2019","journal-title":"Indian J Rheumatol"},{"key":"2024091608262088300_keae167-B19","doi-asserted-by":"crossref","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"2024091608262088300_keae167-B20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/rheumatology\/kez238","article-title":"Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study","volume":"59","author":"Kaneko","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024091608262088300_keae167-B21","author":"STROBE_checklist_v4_cross-sectional.pdf"},{"key":"2024091608262088300_keae167-B22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/injr.injr_56_20","article-title":"Combined case record forms for collaborative datasets of patients and controls of idiopathic inflammatory myopathies","volume":"15","author":"Mehta","year":"2020","journal-title":"Indian J Rheumatol"},{"key":"2024091608262088300_keae167-B23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"2024091608262088300_keae167-B24","volume-title":"Practical statistics for medical research","author":"Altman","year":"1991"},{"key":"2024091608262088300_keae167-B25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2024091608262088300_keae167-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v034.i12","article-title":"glmulti: an R Package for Easy Automated Model Selection with (Generalized) Linear Models","volume":"34","author":"Calcagno","year":"2010","journal-title":"Journal of Statistical Software"},{"key":"2024091608262088300_keae167-B27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-020-02210-2","article-title":"The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis","volume":"22","author":"Tansley","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024091608262088300_keae167-B28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024091608262088300_keae167-B29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2024091608262088300_keae167-B30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdermsci.2021.05.005","article-title":"Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: a Japanese multi-centre adult myositis patients' cohort","volume":"103","author":"Ueda-Hayakawa","year":"2021","journal-title":"J Dermatol Sci"},{"key":"2024091608262088300_keae167-B31","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1093\/rheumatology\/keac039","article-title":"Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort","volume":"61","author":"He","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024091608262088300_keae167-B32","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1097\/RHU.0000000000001350","article-title":"Myositis-Specific Antibodies and Myositis-Associated Antibodies in Patients With Idiopathic Inflammatory Myopathies From the PANLAR Myositis Study Group","volume":"27","author":"Gonzalez-Bello","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2024091608262088300_keae167-B33","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1007\/s10067-021-05797-2","article-title":"Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology","volume":"40","author":"Gomez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2024091608262088300_keae167-B34","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology"},{"key":"2024091608262088300_keae167-B35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024091608262088300_keae167-B36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jalm\/jfab108","article-title":"Myositis antibodies and interstitial lung disease","volume":"7","author":"Basuita","year":"2022","journal-title":"J Appl Lab Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae167\/57228806\/keae167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2363\/59135580\/keae167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2363\/59135580\/keae167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:27:01Z","timestamp":1726475221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2363\/7628322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae167","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,13]]}}}